Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and ...

Nvidia shares have been under pressure since late January, when the release of a lower cost artificial intelligence (AI) ...

Health-care companies fell as traders retreated from some of the highest risk issues.

Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Roche (CH:ROG) shares rose as well, gaining 46in Zurich. Ozempic maker Novo Nordisk (DK:NOVO.B) (NVO), which along with Eli Lilly (LLY) dominates the weight-loss category, slumped 4%, though the ...

and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed ...

Investing.com – Denmark stocks were lower after the close on Wednesday, as losses in the Healthcare, Personal & Household Goods ...

U.S. equities were mixed at midday as the markets weighed a better-than-expected report on inflation and more tariff news.

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...